Welcome to our dedicated page for Whitehawk Therapeutics SEC filings (Ticker: WHWK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Whitehawk is a clinical-stage oncology therapeutics company focused on antibody-drug conjugate (ADC) cancer treatments, and its filings offer insight into financial results, development plans and corporate activities related to this strategy.
Among the key documents available are current reports on Form 8-K, which Whitehawk has used to furnish press releases announcing quarterly financial results and recent highlights. These filings reference information such as research and development spending, progress toward Investigational New Drug (IND) submissions for ADC programs like HWK-007 and HWK-016, and updates on the company’s three-asset ADC portfolio targeting PTK7, MUC16 and SEZ6.
On this page, users can also locate Whitehawk’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain more detailed discussions of the company’s oncology pipeline, risk factors, and financial condition. For investors interested in governance and compensation matters, proxy materials and related filings can provide additional context on board and executive oversight of the ADC development strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major updates without having to parse every page. Real-time updates from the SEC’s EDGAR system ensure that new WHWK filings, including future 10-Ks, 10-Qs and 8-Ks, appear promptly. Users can also review insider transaction reports on Form 4, when available, to see reported trades by directors and officers.
Together, these resources give a structured view of how Whitehawk reports its financial performance, clinical progress and corporate decisions to regulators and the market.
Whitehawk Therapeutics reported Q3 2025 results marked by its transition to a preclinical ADC portfolio. The quarter showed $0 revenue and a net loss of $17.7 million, driven by $19.5 million in operating expenses and offset by $1.9 million in interest income. For the nine months, the company recorded net income of $2.7 million, primarily due to an $87.3 million gain on the FYARRO business sale.
Liquidity strengthened with cash, cash equivalents and short‑term investments of $162.6 million as of September 30, 2025. The company paid $38.0 million plus 6% VAT in April 2025 under its WuXi Biologics license covering three ADCs (MUC16, PTK7, SEZ6). The FYARRO divestiture closed for $102.4 million on March 25, 2025, and a March 2025 private placement added $94.4 million net. An ATM of up to $75.0 million remains unused. Shares outstanding were 47,128,362 as of November 4, 2025.
Whitehawk Therapeutics reported that it issued a press release announcing financial results for the quarter ended September 30, 2025. The release is included as Exhibit 99.1 and is incorporated by reference.
The company states the information under Item 2.02 and Item 9.01 (including Exhibit 99.1) is being furnished, not filed, and therefore is not subject to the liabilities of Section 18 of the Exchange Act, unless specifically incorporated by reference elsewhere.
Coastlands-related parties report beneficial ownership of 2,819,215 shares of Whitehawk Therapeutics common stock, representing 5.98% of the outstanding shares based on 47,128,362 shares cited as of August 4, 2025. The holdings are reported across Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC and Matthew D. Perry. Voting and dispositive power is reported as shared for most entities, with Coastlands Capital GP LLC showing sole voting and dispositive power in one cover-sheet entry, while other reporting persons indicate shared power. The filing states the securities were acquired and are held in the ordinary course of business and are not intended to change or influence control of the issuer.
In its first quarter post-divestiture, Whitehawk Therapeutics (WHWK) filed a Q2 2025 10-Q showing a markedly stronger balance sheet and a shift to pre-clinical R&D.
Liquidity: Cash, cash equivalents and short-term investments rose to $177.2 M from $47.2 M at YE-24, funded by the $102.4 M sale of FYARRO (closed 25 Mar 25) and a $100 M PIPE (21.6 M shares & 20.1 M pre-funded warrants at $2.40).
Operations: With FYARRO gone, Q2 revenue fell to $0 (vs $6.2 M). R&D expense jumped to $48.8 M (Q2 24: $13.1 M) after paying the remaining $38 M WuXi license fee for three antibody-drug conjugate (ADC) programs. SG&A declined 25 % YoY to $5.9 M. Net loss widened to $52.6 M (-$0.76/sh).
Six-month view: An $87.4 M gain on the FYARRO sale produced $20.4 M net income for 1H 25, yet operating cash burn reached $64.8 M.
- Total assets: $180.8 M; liabilities: $8.8 M; no debt.
- Equity climbed to $172.1 M and shares outstanding to 47.1 M (8 Aug 25).
- Outstanding dilution: 22.1 M pre-funded warrants & 7.6 M options.
Outlook: Management believes current cash funds ≥12 months of accelerated ADC development; future value creation now hinges on advancing these pre-clinical candidates into the clinic.